Schwarz and colleagues found that induction of neuregulin-1 and autocrine activation of HER3-PI3K mediates acquired resistance to T-DM1 in HER2+ breast cancer xenografts [61]. The gene discussed is ERBB2; the disease is breast carcinoma.